Scan (company)

GYDER® Surgical announces successful first surgical cases in India

Retrieved on: 
Tuesday, January 2, 2024

The cases were performed in Nov 2023, by Dr. Supreet Bajwa, a fellowship trained orthopedic surgeon and a leader in the Anterior Approach for Total Hip Arthroplasty.

Key Points: 
  • The cases were performed in Nov 2023, by Dr. Supreet Bajwa, a fellowship trained orthopedic surgeon and a leader in the Anterior Approach for Total Hip Arthroplasty.
  • Surgeries using the system were performed at two leading hospitals, Narayan Hrudalaya and the Sanjay Gandhi Orthopaedic and Trauma Hospital, in Bengaluru, India.
  • Developed by GYDER® Surgical, the innovation does not rely on pre-operative or intra-operative imaging such as CT ( Computer Tomography ) or X-ray technology for anatomical landmark registration.
  • Coupled with the Anterior Approach, we embark on a surgical journey where meticulous accuracy, simple workflow, and transformative experience converge, shaping the future of orthopedic excellence in India."

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

Retrieved on: 
Wednesday, December 20, 2023

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.

Key Points: 
  • The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.
  • Analysis of the baseline characteristics of all patients randomized in the main cohort suggests a patient profile aligned with those of patients randomized in the NATIVE Phase II clinical trial.
  • Lanifibranor continues to show a favorable tolerability profile as confirmed by the third Data Monitoring Committee2 of November 2023.
  • Topline results of the proof-of-concept Phase II clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin are expected in the first quarter of 2024.

GK Financing LLC, a Subsidiary of American Shared Hospital Services, Announces Upgrading at Ecuador Center (GKCE) with State-of-the-Art Gamma Knife ICON

Retrieved on: 
Tuesday, November 28, 2023

The total downtime for removal, installation and acceptance testing took just six weeks to perform.

Key Points: 
  • The total downtime for removal, installation and acceptance testing took just six weeks to perform.
  • The entire medical team participated in our first ICON case and are exhilarated with the expanded clinical outcomes.
  • The Gamma Knife ICON offers more clinical throughput, features, and benefits to patients, such as faster treatment times, masked-based immobilization, and same day CT Imaging and treatments when applicable.
  • These expanded options will benefit our patients in Ecuador in their fight against cancer.”

Global Medical Imaging Equipment Services Market Report 2023-2030: Rise in Third Party Imaging Centers Result in Increased Demand for Timely Servicing - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 30, 2023

Market Share of Leading Players in Global Medical imaging equipment Market: 2020

Key Points: 
  • Market Share of Leading Players in Global Medical imaging equipment Market: 2020
    Market Share of Leading Players in Global CT Scanners Market: 2020
    Market Share of Leading Players in Global MRI Equipment Market: 2020
    Market Share of Leading Players in the Global Ultrasound Equipment Market: 2020
    Persistent Need to Maintain Fully-Conditioned Imaging Equipment: Cornerstone for Growth
    Global Medical Imaging Equipment Market by Modality (2020): Percentage Breakdown of Revenues for Computer Tomography (CT), MRI, Nuclear Imaging, Ultrasound and X-Ray Equipment
    Rise in Deployment & Usage of Imaging Equipment Across Modalities: A Review
    Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    Rising Prevalence of Chronic Diseases Amplifies the Volume of Diagnostic Imaging Procedures: Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030

Siteman Cancer Center Begins Treatment with Latest Mevion Proton Therapy System

Retrieved on: 
Thursday, November 16, 2023

Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.

Key Points: 
  • Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.
  • View the full release here: https://www.businesswire.com/news/home/20231116635095/en/
    The MEVION S250i Proton Therapy System (Photo: Business Wire)
    Siteman Cancer Center is an NCI-designated Comprehensive Cancer Center that draws patients from Missouri, Southern Illinois and beyond.
  • “Our team also looks forward to advancing FLASH dosimetry research.”
    This latest system incorporates Mevion's cutting-edge HYPERSCAN® Pencil Beam Scanning for Intensity Modulated Proton Therapy (IMPT) with a proton MLC, along with an advanced 3D imaging system for high-precision Image-Guided Radiation Therapy (IGRT) and adaptive therapy.
  • These latest capabilities are the result of a collaborative effort between Mevion and Siteman Cancer Center, initiated in 2019.

Neogen®, Cat Fanciers' Association Collaborate to Advance Feline DNA Testing

Retrieved on: 
Thursday, December 14, 2023

LINCOLN, Neb., Dec. 14, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that it is collaborating with the Cat Fanciers' Association (CFA), a leading authority in feline advocacy.

Key Points: 
  • LINCOLN, Neb., Dec. 14, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that it is collaborating with the Cat Fanciers' Association (CFA), a leading authority in feline advocacy.
  • "We are excited about this relationship with the Cat Fanciers' Association," said Dr. Robert Westra, Associate Medical Director at Neogen.
  • "This strategic collaboration will not only advance feline DNA testing but also strengthen the bond between Neogen and the feline community.
  • The Cat Fanciers' Association, Inc., a not-for-profit association of member clubs and the world's most influential registry of pedigreed cats, has been preserving, celebrating, and protecting cats since 1906.

Affidea expands its presence in Europe with acquisitions in Spain and Romania

Retrieved on: 
Tuesday, December 5, 2023

Guy Blomfield, Chairman and CEO of Affidea Group, commented on this milestone, saying, "Affidea has significantly expanded its presence in 2023, completing a total of 14 acquisitions in eight countries, adding 25 new centres.

Key Points: 
  • Guy Blomfield, Chairman and CEO of Affidea Group, commented on this milestone, saying, "Affidea has significantly expanded its presence in 2023, completing a total of 14 acquisitions in eight countries, adding 25 new centres.
  • Today, we are thrilled to extend our presence in Spain and Romania, two markets with great potential.
  • With these acquisitions, Affidea reaches a team of 13.000 professionals across 15 countries, serving more than 13 million patients every year at the Group level.
  • These acquisitions represent a significant step forward for Affidea as the company continues to expand its presence across Europe, providing high-quality healthcare services that prioritise patient well-being.

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

Retrieved on: 
Monday, November 6, 2023

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.

Key Points: 
  • The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
  • Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  for presentation.
  • The two abstracts show:
    the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
  • the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.

Mevion Selected to Equip BayCare’s Proton Therapy Center in Tampa

Retrieved on: 
Friday, November 3, 2023

Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, is pleased to announce it has been selected by BayCare to equip the St. Joseph’s Hospital Cancer Institute in Tampa with a MEVION S250-FIT Proton Therapy System™*.
  • “BayCare is bringing an advanced proton radiation therapy center to Tampa so patients in our community don’t have to drive to Orlando or beyond to get this level of high-quality care.”
    The MEVION S250-FIT Proton Therapy System is thoughtfully designed to expedite proton therapy project timelines with a compact footprint, reduced construction requirements, and accelerated installation process.
  • “We are dedicated to advancing proton therapy technology and access, and I look forward to making a meaningful difference to patients and families across West Central Florida.”
    *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.
  • Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy.

North America Dominates the Preclinical Imaging Market in 2022 Due to Advanced Research Infrastructure - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023

The global preclinical imaging market is poised for substantial growth, with a projected size of USD 5.95 billion by 2030.

Key Points: 
  • The global preclinical imaging market is poised for substantial growth, with a projected size of USD 5.95 billion by 2030.
  • The market is expected to expand at a Compound Annual Growth Rate (CAGR) of 4.74% from 2023 to 2030.
  • Heavy investments in research and development worldwide are driving research projects and, subsequently, the demand for preclinical imaging.
  • Advancements in high-throughput ultrasound imaging systems used in cancer research and studies have further driven market growth.